There has been a large amount taking place in companion diagnostics in particular.

The importance of this industry is seen in the flurry of activity between companies where one or both are involved in cancer diagnostics. Many of these advances are initially turned into tests as services, most often as LDTs but also FDA-approved or CE-IVD tests. New reagents, bioinformatics, sequencing technologies, and improved histological tests are among the trends in this multifaceted report. Diagnostic tests for effective cancer screening are needed more than ever.Īs this report goes to print several significant developments are taking place. Growth rates in cancer testing tend to be higher than in other IVD fields. With the unfortunate rising statistics of cancer in the developed world, innovation is a must. The application areas are distinct in many ways, but the domains of oncology and inherited/genetic diseases have significant overlap and bridges between them as well as largely sharing advancements in relation to the technologies used.Ĭancer testing is maturing to precision medicine, where numerous biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence for the given patient. While older, PCR continues to be innovated and remains a central tool in molecular diagnostics laboratories of all kinds, and in situ hybridization techniques (ISH) such as FISH are still vital for understanding gene expression and genetic alterations in situ.

For example, next-generation sequencing (NGS) technologies have become widely used in genetic diseases, and have grown rapidly in oncology, due to the comprehensive insights they can provide at a relatively low cost. In recent decades, the introduction of various new genetic technologies for research use and diagnostics has revolutionized many areas and opened new frontiers in healthcare. 25, 2024 (GLOBE NEWSWIRE) - The 'Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028' report has been added to 's offering.

Qiagen molecular diagnostics